[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ca32ed69f6980c3e14880cf8fa5ceffa7210e8fe380cf608f932ecc17cd3dc0f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747845900,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 134639217,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ca32ed69f6980c3e14880cf8fa5ceffa7210e8fe380cf608f932ecc17cd3dc0f"
    }
  },
  {
    "ts": null,
    "headline": "Viz.ai, Sanofi and Regeneron to link for COPD management",
    "summary": "The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination.",
    "url": "https://finnhub.io/api/news?id=1ea507fbb13416b455ca308a91f7df12bfa924ff067f21c73ec73f238b09e75a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747839108,
      "headline": "Viz.ai, Sanofi and Regeneron to link for COPD management",
      "id": 134628752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination.",
      "url": "https://finnhub.io/api/news?id=1ea507fbb13416b455ca308a91f7df12bfa924ff067f21c73ec73f238b09e75a"
    }
  },
  {
    "ts": null,
    "headline": "Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts. The acquisition includes 23andMe’s Personal Genome Service, Total Health, Research Services divisions, its Biobank, and associated infrastructure. Regeneron plans to keep consumer services running without disruption and expects the transaction to close in the thi",
    "url": "https://finnhub.io/api/news?id=02b2bab964536ef5e97490538f88d1eafdfb976a2aa68ccd3156bb98bf1ecea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747820716,
      "headline": "Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal",
      "id": 134628753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts. The acquisition includes 23andMe’s Personal Genome Service, Total Health, Research Services divisions, its Biobank, and associated infrastructure. Regeneron plans to keep consumer services running without disruption and expects the transaction to close in the thi",
      "url": "https://finnhub.io/api/news?id=02b2bab964536ef5e97490538f88d1eafdfb976a2aa68ccd3156bb98bf1ecea9"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains",
    "summary": "Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=f60cb54f9828cd254225b486eefba1773217ad8b22d7c40ee41f5da5d5fea347",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747808110,
      "headline": "Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains",
      "id": 134623938,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1194975085/image_1194975085.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=f60cb54f9828cd254225b486eefba1773217ad8b22d7c40ee41f5da5d5fea347"
    }
  },
  {
    "ts": null,
    "headline": "3 Cash-Producing Stocks in Hot Water",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=6ab9109cf5f1503ee4d14fab9b9863cdf459b837df69856d758f43d69677ab6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747802233,
      "headline": "3 Cash-Producing Stocks in Hot Water",
      "id": 134628754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=6ab9109cf5f1503ee4d14fab9b9863cdf459b837df69856d758f43d69677ab6d"
    }
  }
]